PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1

Journal of Cellular and Molecular Medicine

Volumn 17, Issue 2, 2013, Pages 233-241

  Pinton, Giulia ^a   Manente, Arcangela Gabriella ^a   Murer, Bruno ^b   De Marino, Elvira ^c   Mutti, Luciano ^c   Moro, Laura ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b Mestre Hospital   (Italy)

^c Vercelli Hospital   (Italy)

Author keywords

AKT mTOR axis; Malignant pleural mesothelioma; PARP1; PARP1 inhibitor; Therapeutic target

Indexed keywords

MTOR PROTEIN, HUMAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PARP1 PROTEIN, HUMAN; PROTEIN KINASE B; SIRT1 PROTEIN, HUMAN; SIRTUIN 1; TARGET OF RAPAMYCIN KINASE;

ACETYLATION; ADULT; AGED; APOPTOSIS; ARTICLE; CELL CYCLE; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; ENZYME IMMUNOASSAY; FEMALE; HUMAN; IMMUNOPRECIPITATION; MALE; MESOTHELIOMA; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PHOSPHORYLATION; PROGNOSIS; SURVIVAL RATE; VERY ELDERLY; WESTERN BLOTTING;

ACETYLATION; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; MALE; MESOTHELIOMA; MIDDLE AGED; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; SIRTUIN 1; SURVIVAL RATE; TOR SERINE-THREONINE KINASES;

EID: 84874361039     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12000     Document Type: Article

References (42)

1. Peto J, Decarli A, La Vecchia C, et al. The European mesothelioma epidemic. Br J Cancer. 1999; 79: 666-72.
2. Kroczynska B, Cutrone R, Bocchetta M, et al. Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters. Proc Natl Acad Sci USA. 2006; 103: 14128-33.
3. Kazan-Allen L. Asbestos and mesothelioma: worldwide trends. Lung Cancer. 2005; 49: S3-8.
4. Campbell NP, Kindler HL. Update on malignant pleural mesothelioma. Semin Respir Crit Care Med. 2011; 32: 102-10. Review.
5. Ray M, Kindler HL. Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest. 2009; 136: 888-96. Review.
6. Testa JR, Cheung M, Pei J, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011; 43: 1022-5.
7. Neri M, Ugolini D, Dianzani I, et al. Genetic susceptibility to malignant pleural mesothelioma and other asbestos-associated diseases. Mutat Res. 2008; 659: 126-36.
8. Carbone M, Emri S, Dogan AU, et al. A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes. Nat Rev Cancer. 2007; 7: 47-54.
9. Carbone M, Bedrossian CW. The pathogenesis of mesothelioma. Semin Diagn Pathol. 2006; 23: 56-60.
10. Yang H, Rivera Z, Jube S, et al. Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci USA. 2010; 107: 12611-6.
11. Ame JC, Spenlehauer C, de Murcia G. The PARP superfamily. BioEssays. 2004; 26: 882-93.
12. Virág L. Poly(ADP-ribosyl)ation in asthma and other lung diseases. Pharmacol Res. 2005; 52: 83-92.
13. Malanga M, Althaus FR. The role of poly(ADP-ribose) in the DNA damage signaling network. Biochem Cell Biol. 2005; 83: 354-64.
14. Rouleau M, Patel A, Hendzel MJ, et al. PARP inhibition: PARP1 and beyond. Nat Rev Cancer. 2010; 10: 293-301.
15. Curtin NJ. PARP inhibitors for cancer therapy. Expert Rev Mol Med. 2005; 7: 1-20.
16. Munoz-Gamez JA, Martin-Oliva D, Aguilar-Queseda R, et al. PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis. Biochem J. 2005; 386: 119-25.
17. Cheng CL, Johnson SP, Keir ST, et al. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol Cancer Ther. 2005; 4: 1364-8.
18. Shall S, de Murcia G. Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model? Mutat Res. 2000; 460: 1-15.
19. Wilson SM, Barbone D, Yang TM, et al. mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids. Am J Respir Cell Mol Biol. 2008; 39: 576-83.
20. Sarszegi Z, Bognar E, Gaszner B, et al. BGP-15, a PARP-inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases. Mol Cell Biochem. 2012; 365: 129-37.
21. Szanto A, Hellebrand EE, Bognar Z, et al. PARP-1 inhibition-induced activation of PI-3-kinase-Akt pathway promotes resistance to taxol. Biochem Pharmacol. 2009; 77: 1348-57.
22. Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999; 17: 1474-81.
23. Smythe WR, Kaiser LR, Hwang HC, et al. Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma. Ann Thorac Surg. 1994; 57: 1395-401.
24. Bepler G, Koehler A, Kiefer P, et al. Characterization of the state of differentiation of six newly established human non-small-cell lung cancer cell lines. Differentiation. 1988; 37: 158-71.
25. Tallarida RJ. An Overview of Drug Combination Analysis with Isobolograms. J Pharmacol Exp Ther. 2006; 19: 1-7.
26. Tallarida RJ. Drug synergism: its detection and applications. J Pharmacol Exp Ther. 2001; 298: 865-72. Review.
27. Mujoomdar AA, Tilleman TR, Richards WG, et al. Prevalence of in vitro chemotherapeutic drug resistance in primary malignant pleural mesothelioma: result in a cohort of 203 resection specimens. J Thorac Cardiovasc Surg. 2010; 140: 352-5.
28. Bai P, Cantó C, Oudart H, et al. PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. Cell Metab. 2011; 13: 461-8.
29. Sundaresan NR, Pillai VB, Wolfgeher D et al. The deacetylase SIRT1 promotes membrane localization and activation of Akt and PDK1 during tumorigenesis and cardiac hypertrophy. Sci Signal. 2011; 4: ra46.
30. Wang Z, Wang F, Tang T, et al. The role of PARP1 in the DNA damage response and its application in tumor therapy. Front Med. 2012; 6: 156-64.
31. Rottenberg S, Jaspers JE, Kersbergen A, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA. 2008; 105: 17079-84.
32. Donawho CK, Luo Y, Penning TD, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res. 2007; 13: 2728-37.
33. Hiller DJ, Chu QD. Current status of poly(ADP-ribose) polymerase inhibitors as novel therapeutic agents for triple-negative breast cancer. Int J Breast Cancer. 2012; 829315: Review.
34. Tomasetti M, Amati M, Nocchi L, et al. Asbestos exposure affects poly(ADP-ribose) polymerase-1 activity: role in asbestos-induced carcinogenesis. Mutagenesis. 2011; 26: 585-91.
35. Pacher P, Szabó C. Role of poly(ADP-ribose) polymerase 1 (PARP1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors. Cardiovasc Drug Rev. 2007; 25: 235-60.
36. Luo X, Kraus WL. A One and a Two... Expanding Roles for Poly(ADP-Ribose) Polymerases in metabolism. Cell Metab. 2011; 13: 353-5.
37. Ghosh HS, McBurney M, Robbins PD. SIRT1 negatively regulates the mammalian target of rapamycin. PLoS ONE. 2010; 5: e9199.
38. Wang RH, Kim HS, Xiao C, et al. Hepatic Sirt1 deficiency in mice impairs mTorc2/Akt signaling and results in hyperglycemia, oxidative damage, and insulin resistance. J Clin Invest. 2011; 121: 4477-90.
39. Barbone D, Yang TM, Morgan JR, et al. Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids. J Biol Chem. 2008; 283: 13021-30.
40. Harada H, Andersen JS, Mann M, et al. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci USA. 2001; 98: 9666-70.
41. Panner A, James CD, Berger MS, et al. mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol Cell Biol. 2005; 20: 8809-23.
42. Busacca S, Sheaff M, Arthur K, et al. BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma. J Pathol. 2012; 227: 200-8.